1Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
2Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea
3Division of Hematology-Oncology, Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine, Incheon, Korea
4Division of Medical Oncology, Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea
5Department of Hematology/Oncology, Keimyung Unversity Dongsan Hospital, Daegu, Korea
6Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Korea
7Division of Hematology and Oncology, Department of Internal Medicine, Dongnam Institute of Radiological and Medical Sciences, Busan, Korea
8Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
9Division of Hematology-Oncology, Department of Internal Medicine, Gyeongsang Institute of Health Sciences, Gyeongsang National University College of Medicine and Gyeongsang National University Changwon Hospital, Changwon, Korea
10Department of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea
11Division of Hematology and Oncology, Department of Internal Medicine, National Medical Center, Seoul, Korea
12Division of Hematology/Oncology, Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University School of Medicine, Daejeon, Korea
13Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea
14Division of Medical Oncology and Hematology, Department of Internal Medicine, Kyunghee University Hospital, Seoul, Korea
15Division of Hematology and Oncology, Department of Internal Medicine, Inje University Paik Hospital, Busan, Korea
16Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA
Copyright © 2019 by the Korean Cancer Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
This study was supported in part by Lilly, Korea. However, the funder had no role in the study design, data collection and analysis, decision to publish, or preparation of this manuscript.
PC (n=46) |
P (n=45) |
PC+P (n=91) |
|||||||
---|---|---|---|---|---|---|---|---|---|
Gr 1-2 | Gr ≥ 3 | Total | Gr 1-2 | Gr ≥ 3 | Total | Gr 1-2 | Gr ≥ 3 | Total | |
Fatigue | 14 | 0 | 14 | 10 | 1 | 11 | 24 | 1 | 25 |
GI toxicity | 22 | 4 | 26 | 18 | 0 | 18 | 40 | 4 | 44 |
Bleeding or thrombocytopenia | 1 | 0 | 1 | 1 | 0 | 1 | 2 | 0 | 2 |
Neutropenia | 1 | 2 | 3 | 0 | 3 | 3 | 1 | 5 | 6 |
Neurotoxicity | 8 | 0 | 8 | 2 | 0 | 2 | 10 | 0 | 10 |
Skin and alopecia | 5 | 0 | 5 | 8 | 0 | 8 | 13 | 0 | 13 |
Myalgia and arthralgia | 2 | 0 | 2 | 4 | 0 | 4 | 6 | 0 | 6 |
Othersa) | 25 | 8 | 33 | 27 | 5 | 32 | 52 | 13 | 65 |
PC (n=48) | P (n=48) | Total (n=96) | p-value | |
---|---|---|---|---|
Age (yr) | 60 (32-82) | 64 (31-84) | 62 (31-84) | 0.133 |
Male sex | 11 (23) | 15 (31) | 26 (27) | 0.358 |
Smoking, yes | 9 (19) | 16 (33) | 25 (26) | 0.014 |
ECOG | ||||
0 | 9 (19) | 5 (10) | 14 (15) | 0.247 |
1 | 39 (81) | 43 (90) | 82 (85) | |
EGFR mutation | ||||
Deletion exon 19 | 32 (67) | 32 (67) | 64 (67) | > 0.999 |
L858R | 16 (33) | 16 (33) | 32 (33) | |
Stage IV | 48 (100) | 48 (100) | 96 (100) | > 0.999 |
Recurrence | 1 (2) | 7 (15) | 8 (8) | 0.029 |
Metastatic | 47 (98) | 41 (85) | 88 (92) | |
Surgery | 6 (13) | 9 (19) | 15 (16) | 0.399 |
Radiotherapy | 4 (8) | 8 (17) | 12 (13) | 0.178 |
PC (n=46) |
P (n=45) |
PC+P (n=91) |
|||||||
---|---|---|---|---|---|---|---|---|---|
Gr 1-2 | Gr ≥ 3 | Total | Gr 1-2 | Gr ≥ 3 | Total | Gr 1-2 | Gr ≥ 3 | Total | |
Fatigue | 14 | 0 | 14 | 10 | 1 | 11 | 24 | 1 | 25 |
GI toxicity | 22 | 4 | 26 | 18 | 0 | 18 | 40 | 4 | 44 |
Bleeding or thrombocytopenia | 1 | 0 | 1 | 1 | 0 | 1 | 2 | 0 | 2 |
Neutropenia | 1 | 2 | 3 | 0 | 3 | 3 | 1 | 5 | 6 |
Neurotoxicity | 8 | 0 | 8 | 2 | 0 | 2 | 10 | 0 | 10 |
Skin and alopecia | 5 | 0 | 5 | 8 | 0 | 8 | 13 | 0 | 13 |
Myalgia and arthralgia | 2 | 0 | 2 | 4 | 0 | 4 | 6 | 0 | 6 |
Others |
25 | 8 | 33 | 27 | 5 | 32 | 52 | 13 | 65 |
Values are presented as median (range) or number (%). PC, pemetrexed plus cisplatin combination followed by maintenance pemetrexed; P, pemetrexed only; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor.
PC, pemetrexed plus cisplatin combination followed by maintenance pemetrexed; P, pemetrexed only; Gr, grade; GI, gastrointestinal. Others include headache, insomnia, dyspnea and pain on other sites than muscles and joints.